Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?
The first large real-world evidence study has found SGLT2 inhibitors cut the rate of hospitalizations for heart failure and all-cause mortality in patients at low risk of cardiovascular events, but the results of CV outcomes studies are awaited to confirm the findings.
You may also be interested in...
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.
The EMA is looking at a marketing authorization variation for the type 2 diabetes blockbuster SGLT-2 inhibitor for use as an oral adjunct treatment to insulin in adults with type 1. Observers will be interested to see what stance the agency takes on the slightly higher number of diabetic ketoacidosis events seen in trials supporting the submission.
Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.